Salarius Pharmaceuticals(US:SLRX) Globenewswire·2026-01-07 13:45Core Viewpoint - Salarius Pharmaceuticals, Inc. will change its name to Decoy Therapeutics Inc. and its shares will trade under the ticker symbol DCOY starting January 8, 2026, reflecting a strategic focus on developing peptide-conjugate therapeutics [2][3] Group 1: Corporate Changes - The name change to Decoy Therapeutics Inc. signifies a transformation towards developing next-generation peptide-conjugate therapeutics, particularly targeting viral and oncology diseases [3] - The transition does not affect the total number of shares outstanding, shareholders' rights, or the company's operations and leadership [3] Group 2: Strategic Focus and Pipeline - Decoy Therapeutics is advancing a proprietary peptide-conjugate platform aimed at selectively targeting high-value biological threats, with initial programs focusing on pan-coronavirus activity and other viral threats like influenza and RSV [4] - The lead antiviral program has garnered interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning the company for potential non-dilutive funding and partnerships [4][9] Group 3: 2026 Execution Plan - The company's 2026 plan emphasizes execution, data generation, and achieving multiple value-creating milestones while maintaining capital efficiency [6] - Key priorities include advancing lead antiviral programs towards regulatory readiness and expanding discovery and preclinical validation across various platforms [8] Group 4: Funding and Collaborations - Decoy has attracted financing from institutional investors and significant capital from various sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [9] - The company is pursuing strategic collaborations with big pharmaceutical companies, technology leaders, and academic institutions to enhance its development capabilities [8]